Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF 69 Receivables Turnover is 0.49 as of Dec. 2025. GuruFocus rates CASBF with a GF Score™ of 69/100 and a GF Value™ of $8.73 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 950 Drug Manufacturers companies, CanSino Biologics ranks worse than 97.89% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. CanSino Biologics's Revenue for the
three
months ended in Dec. 2025 was $52.08 Mil. CanSino Biologics's average Accounts Receivable for the
three
months ended in Dec. 2025 was $106.63 Mil.
Hence, CanSino Biologics's Receivables Turnover for the
three
months ended in Dec. 2025 was 0.49.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
CanSino Biologics Receivables Turnover Related Terms
CanSino Biologics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASBF vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics (CASBF) has a Receivables Turnover of 0.49 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CanSino Biologics and its competitors. According to the industry distribution chart, CanSino Biologics ranks #930 out of 950 companies in the Drug Manufacturers industry, placing it in the top 97.9%.
Is CanSino Biologics' Receivables Turnover too high?
CanSino Biologics' current Receivables Turnover is 0.49. The Drug Manufacturers industry median Receivables Turnover is 5.07. CanSino Biologics' value of 0.49 is 90.3% below this industry median. Based on the distribution chart, CanSino Biologics ranks #930 out of 950 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CanSino Biologics has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #930 out of 950 companies for Receivables Turnover. This places CanSino Biologics in the lower half of its industry. The industry median Receivables Turnover is 5.07. CanSino Biologics' value of 0.49 is 90.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current Receivables Turnover of 0.49 is 90.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current Receivables Turnover is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.73, compared to a current price of $2.60 — trading 70.2% below its estimated fair value. The current Receivables Turnover is 0.49 and 90.3% below the Drug Manufacturers industry median of 5.07. CanSino Biologics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Receivables Turnover is 0.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $2.60 is trading 70.2% below its estimated GF Value™ of $8.73.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
Receivables Turnover: 0.49
GF Value™: $8.73 vs. price of $2.60 (70.2% below fair value)
Industry Position: 90.3% below the Drug Manufacturers median (#930 of 950)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
69GF Score
Get the complete analysis for CASBF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
